Why manufacturer is recalling hospital blood pressure drug
Hospital pharmacies need to check their supplies of norepinephrine after PharMEDium Services in Lake Forest, Ill., voluntarily recalled several lots of Norepinephrine Bitartrate. The product is used to control blood pressure in certain acute hypotensive states.
Hospital pharmacies need to check their supplies of norepinephrine after PharMEDium Services in Lake Forest, Ill., voluntarily recalled several lots of Norepinephrine Bitartrate. The product is used to control blood pressure in certain acute hypotensive states.
Related: FDA warns of joint pain for DPP-4 diabetes drugs
In late December, PharMEDium recalled 29 lots of 4-mg Norepinephrine Bitartrate (16 μg/mL) added to 0.9% Sodium Chloride in 250-mL Viaflex Bag and 3 lots of 8 mg. Norepinephrine Bitartrate (32 μg/mL) added to 0.9% Sodium Chloride in 250-mL Viaflex Bag distributed to hospitals.
Related: FDA, PatientsLikeMe partner on drug safety data
“We have received complaints from hospitals for products that have been found to exhibit a slight discoloration in the admixture. The drug manufacturer's prescribing information advises not to use the product if it is discolored,” according to a statement from the company. Discoloration indicates degradation and could result in decreased potency, due to oxidation of Norepinephrine Bitartrate.
While decreased potency may result in a delay of achieving desired therapeutic effect, PharMEDium Services has not received any reports of adverse events related to the recall.
Meanwhile, hospital pharmacies that have the recalled Norepinephrine Bitartrate products should stop using and discard per the hospital destruction policy, PharMEDium said. “Hospitals that may have shared these products with other hospitals should contact those hospitals that received the products.”
A full listing of the recalled lots can be found here: http://www.fda.gov/Safety/Recalls/ucm479677.htm.
Hospitals or other healthcare providers with questions regarding the recall can contact PharMEDium Services at 847-457-2244 or email quality1@pharmedium.com.
Read more: Lutera is latest birth control recall
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
